Cyproheptadine-d3
Cyproheptadine-d3 is the d3-labeled Cyproheptadine (HY-B1622). Cyproheptadine acts as a p38 MAP kinase activator, CHK2 activator, histamine H1 receptor inhibitor and serotonin receptor inhibitor. Cyproheptadine mediates cell cycle arrest via G1 phase arrest, G1/S transition arrest, G0/G1 phase arrest, reduced expression of cyclins D1/D2/D3, upregulated expression of HBP1, p16, p21, p27, and decreased phosphorylation of retinoblastoma protein. Cyproheptadine induces Apoptosis by increasing PARP and cleaved PARP, as well as activating the mitochondrial caspase pathway. Cyproheptadine inhibits tumor growth with extremely low toxicity to normal cells. Cyproheptadine can be used in research related to hepatocellular carcinoma, multiple myeloma and acute myeloid leukemia.
For research use only. We do not sell to patients.
- CAS No.: 2712455-05-3
- Formula: C21H18D3N
- Molecular Weight:290.42
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
|
H1 Receptor |
Chk2 |
CDK1 |
CDK2 |
CDK3 |
1. This compound can be used as a tracer
2. This compound can be used as an internal standard for quantitative analysis by NMR, GC-MS, or LC-MS.
Chemical Information
-
CAS No. 2712455-05-3
-
Unlabeled Cas 129-03-3
-
Molecular Weight 290.42
-
Formula C21H18D3N
-
SMILES
[2H]C([2H])([2H])N1CC/C(CC1)=C2C3=CC=CC=C3C=CC4=CC=CC=C/24
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Feng YM, et al. Cyproheptadine, an antihistaminic drug, inhibits proliferation of hepatocellular carcinoma cells by blocking cell cycle progression through the activation of P38 MAP kinase. BMC Cancer. 2015;15:134. Published 2015 Mar 17. [Content Brief]
[2]. Mao X, et al. Cyproheptadine displays preclinical activity in myeloma and leukemia. Blood. 2008;112(3):760-769. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Cyproheptadine-d3 Related Classifications
HY-B1622S Related Classifications
Powered by Bioz
- Cyproheptadine-d3
- 2712455-05-3
- Isotope-Labeled Compounds
- p38 MAPK
- Checkpoint Kinase (Chk)
- Histamine Receptor
- 5-HT Receptor
- CDK
- PARP
- Apoptosis
- CHK2
- histamine H1 receptor
- LP-1
- hepatocellular carcinoma
- acute myeloid leukemia
- human hematopoietic stem cells
- p38 MAP kinase
- serotonin receptor
- multiple myeloma
- MDAY-D2 cells
- Inhibitor
- inhibitor
- inhibit